KRAS G12D inhibitor QTX3046

{
  "id": "MLC-T-ONC-014670",
  "term": "KRAS G12D inhibitor QTX3046",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable allosteric inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor QTX3046 specifically targets and noncovalently binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis. QTX3046 inhibits both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRAS G12D, and is able to cross the blood-brain barrier (BBB).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/kras-g12d-inhibitor-qtx3046/"
}